Business Context and Reporting Period
Company: PMV Pharmaceuticals, Inc. (PMVP)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: PMV is a clinical-stage precision oncology company developing small molecule, tumor-agnostic therapies targeting p53 mutations. The company's lead product candidate, rezatapopt, is designed to structurally correct the p53 Y220C mutation. The company has no approved products and has not generated any revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(77,742) | $(58,709) |
| Research & Development Expenses | $69,877 | $58,527 |
| General & Administrative Expenses | $16,329 | $26,921 |
| Cash, Cash Equivalents, and Marketable Securities | $112,943 | $183,297 |
| Accumulated Deficit | $(446,454) | $(368,712) |
| Net Cash Used in Operating Activities | $(73,577) | $(51,282) |
Note: The company reported a net loss of $77.7 million for 2025 compared to $58.7 million for 2024. Total operating expenses increased slightly to $86.2 million in 2025 from $85.4 million in 2024.
Material Changes vs. Prior Period
- Increased R&D Spend: Research and development expenses increased by $11.4 million (19.4%) year-over-year, primarily driven by a $13.1 million increase in development and personnel-related costs associated with advancing the Phase 2 clinical trial for rezatapopt.
- Decreased G&A Spend: General and administrative expenses decreased by $10.6 million (39.3%), largely due to a $7.7 million reduction in facility-related costs following the termination of the lease for the company's prior headquarters in Princeton, New Jersey.
- Reduced Interest Income: Net interest income decreased by $4.3 million to $6.3 million, attributed to lower interest rates and a reduction in the amount of cash invested in marketable securities.
- Liquidity Position: Total financial assets (cash, cash equivalents, and marketable securities) decreased by $70.4 million to $112.9 million as the company funded its operating losses.
Guidance, Outlook, and Management Commentary
- Clinical Progress: In September 2025, the company announced interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The data showed an overall response rate (ORR) of 34% across eight tumor types and a 46% ORR in the ovarian cancer cohort. In March 2026, rezatapopt received Orphan Drug Designation (ODD) from the FDA for TP53 Y220C positive ovarian cancer.
- Regulatory Timeline: Management plans to submit a New Drug Application (NDA) to the FDA for rezatapopt in the first quarter of 2027 for the treatment of platinum-resistant/refractory ovarian cancer harboring a TP53 Y220C mutation.
- Liquidity Outlook: As of December 31, 2025, the company held $112.9 million in cash and marketable securities. Management believes these resources are sufficient to fund planned operations until the end of the second quarter of 2027.
- Capital Needs: The company expects to incur significant losses for the foreseeable future and may need to raise additional capital through equity or debt financings, strategic partnerships, or licensing arrangements to complete development and commercialization.
- Risks: Key risks include the failure of clinical trials to demonstrate efficacy, delays in regulatory approval, inability to recruit patients with specific mutations, and the need for substantial additional funding. The company also faces risks related to reliance on third-party manufacturers and potential geopolitical impacts on supply chains.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $112.9 million cash balance to fund operations through Q2 2027, considering potential acceleration of clinical trial costs.
- Clinical Data Validation: Review the full interim data from the Phase 2 PYNNACLE trial (September 2025) to assess the durability of response and safety profile, particularly in the ovarian cancer cohort.
- Regulatory Strategy: Confirm the FDA's acceptance of the tumor-agnostic development strategy and the specific requirements for the planned Q1 2027 NDA submission.
- Manufacturing Dependencies: Assess the company's reliance on third-party contract manufacturing organizations (CMOs), particularly those located in China, and the potential impact of trade tariffs or geopolitical tensions.
- Intellectual Property: Review the status of the 11 issued U.S. patents and 53 granted foreign patents, noting expiration dates between 2037 and 2043, and any pending litigation or challenges.